Nadolol for Primary and Secondary Prophylaxis of Esophageal Variceal Bleeding

Primary Prophylaxis – Medium or Large Varices

In patients with medium‑ or large‑size esophageal varices who have never bled, non‑selective beta‑blockers (including nadolol) prevent one bleeding episode for every ten treated (meta‑analysis of 1,189 cirrhotic patients)【1】.
Nadolol lowers portal pressure by decreasing cardiac output (β1‑blockade) and producing splanchnic vasoconstriction (β2‑blockade), thereby reducing portal blood flow【1】.
Mortality is significantly reduced in cirrhotic patients receiving nadolol compared with untreated controls【1】.

Nadolol is recommended for patients with small varices who have high‑risk features (Child‑B/C cirrhosis or red‑wale marks)【2】.
In a randomized trial, nadolol slowed progression to large varices to 11 % at three years versus 37 % with placebo【2】 (high‑quality evidence).
Continuous, indefinite therapy with nadolol is required; stopping the drug markedly increases the risk of first variceal bleed【2】.

For patients who have already experienced a variceal hemorrhage, nadolol combined with endoscopic variceal ligation is the preferred regimen to reduce rebleeding risk (guideline recommendation)【2】.

Initiate nadolol at 40 mg once daily and titrate upward to the maximal tolerated dose (dose titration is based on tolerance, not solely on heart‑rate reduction)【1】.
The therapeutic goal is a ≥20 % reduction in hepatic venous pressure gradient (HVPG) from baseline or an absolute HVPG < 12 mmHg, thresholds that are associated with near‑elimination of hemorrhage risk【1】.

Adding isosorbide mononitrate to nadolol for primary prophylaxis is not recommended; two large double‑blind, placebo‑controlled trials failed to demonstrate benefit and reported more adverse events【1】.
Co‑administration of spironolactone with nadolol does not improve prevention of first variceal hemorrhage【1】.

Routine endoscopic surveillance is not required in patients maintained on nadolol therapy【1】【2】.
Approximately 11 % of patients develop side‑effects that necessitate dose adjustment or discontinuation, underscoring the need for periodic assessment of heart rate, blood pressure, and renal function【2】.

Non‑selective beta‑blockers (nadolol, propranolol) are superior to selective beta‑blockers (atenolol, metoprolol) for variceal prophylaxis【1】.
Nadolol is clinically equivalent to endoscopic variceal ligation for preventing a first variceal bleed; choice should be individualized based on patient preference and local expertise【1】.
Economic analyses identify nadolol as the only cost‑effective prophylactic option when compared with sclerotherapy or surgical shunt procedures【1】.

The American Association for the Study of Liver Diseases recommends beta blockers for primary prophylaxis in patients with medium/large varices who have not bled, as they significantly reduce the risk of first variceal bleeding from 30% to 14% 3, 4
Beta blockers are indicated in patients with small varices who have high risk of bleeding, such as those with Child B/C cirrhosis or presence of red wale marks on varices 3
Nonselective beta blockers can slow progression from small to large varices, with a reduction in progression from 37% to 11% at 3 years 3

The American Association for the Study of Liver Diseases recommends combination of nonselective beta blockers plus endoscopic variceal ligation for secondary prophylaxis of variceal hemorrhage, as it is the best option for reducing bleeding risk 5, 6
Beta blockers should be adjusted to the maximal tolerated dose and continued indefinitely once started, as discontinuation increases bleeding risk 5, 6

Nonselective beta blockers reduce portal pressure by decreasing cardiac output and producing splanchnic vasoconstriction, which reduces portal blood flow 4
A reduction in hepatic venous pressure gradient of ≥20% from baseline or to <12 mmHg significantly decreases bleeding risk 4

Propranolol is typically started at 40 mg once daily and titrated up to the maximal tolerated dose, rather than targeting heart rate reduction 4
Long-acting propranolol can be used at doses of 80-160 mg daily to improve compliance, but the maximum recommended dose should be reduced to 160 mg daily in patients with ascites 4, 7

Nonselective beta blockers are the preferred choice for variceal prophylaxis, as selective beta blockers are less effective and suboptimal 4
Contraindications to beta blocker use include asthma, severe COPD, heart block, significant bradycardia, hypotension, and decompensated heart failure 4, 8

Regular monitoring of heart rate, blood pressure, and renal function is essential, particularly in patients with end-stage liver disease 7
In patients with small varices not receiving beta blockers, endoscopy should be repeated every 2 years, or annually if there is evidence of hepatic decompensation 3